Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Ludwig Hantson

- PMLiVE

Building the capabilities for a new ‘patient access’ model

Equipping employees for purpose-driven performance

Shire Basingstoke

Shire launches long-acting ADHD drug Intuniv in UK

Also plans to launch the once-daily treatment in Japan later this year

- PMLiVE

Baxalta makes $1.7bn play for slice of CAR-T market

Three-year alliance with Precision BioSciences to expand immuno-oncology portfolio

- PMLiVE

Challenging perceptions

Alvaro Herreros on the ADHD landscape

EU flag

Baxalta’s rare blood cancer drug Oncaspar approved in Europe

First EU-wide licence for the acute lymphoblastic leukaemia treatment

- PMLiVE

Baxalta agrees to $32bn Shire takeover

Deal will  create one of the industry's top rare disease firms

- PMLiVE

Baxalta and CTI complete filing for Jakafi rival in US

Myelofibrosis candidate pacritinib aiming for accelerated approval

- PMLiVE

Baxalta inks $1.6bn immuno-oncology deal with Symphogen

Comes as the company's takeover negotiations with Shire continue

Shire Basingstoke

Shire deal with Baxalta predicted this week

Takeover talks reported to be at an advanced stage

- PMLiVE

First von Willebrand disease therapy heads new FDA approvals

Baxalta's Vonvendi set for an early 2016 launch in the US

- PMLiVE

Baxter appoints Jose Almeida chairman and CEO

Will take over from Robert Parkinson Jr in Janary

Shire Basingstoke

FDA grants fast track designation to Shire’s Cinryze

Kidney transplant treatment in line for regulatory assistance

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links